Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on April 24, 2025

GENFIT : Résultats financiers annuels 2024 et point sur les activités de la Société
Trésorerie et équivalents de trésorerie s’élevant à 81,8 millions d’euros au 31 décembre 2024. En outre, conclusion, en début d’année (i) d’un accord de royalty financing non dilutif d'un montant maximum de 185 millions d'euros comprenant un versement …

Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025
FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The …

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025
MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to …

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)
GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …

Treace to Report First Quarter 2025 Financial Results on May 8, 2025
PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities …

Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it …

FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced the publication of a groundbreaking paper in the journal Science Advances detailing the development …

Seer to Report First Quarter 2025 Financial Results on May 13, 2025
REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 …

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance
First Quarter Highlights† Reported revenue of $355.4 million, up 9.8% Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectively GAAP operating margin of 11.5%, compared to 11.1% in prior year period Non-GAAP …

Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society
Fort Mill, S.C., April 24, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their …

PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation …

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological …

Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor
► Des signatures de biomarqueurs ont été développées pour prédire la réponse histologique au traitement par lanifibranor chez les patients atteints de MASH avec fibrose ► Les signatures de biomarqueurs développées pour l’amélioration de la fibrose, la …

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.S. financial …

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 …

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the …

Exploring the Genome: How Creative Biolabs Leads the Way in the Future of CRISPR Gene Editing
In the vast territories of the genome, Creative Biolabs uses CRISPR gene-editing technologies to rewrite the rules of genetic research and therapy development. SHIRLEY, NY, UNITED STATES, April 24, 2025 /EINPresswire.com/ -- The CRISPR-Cas9 system has …

Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, …

May is Brain Cancer Awareness Month: Illuminate the Fight Against One of the Most Lethal Cancers
TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- This May, Brain Cancer Canada (BCC) and communities across the country prepare to rally for Brain Cancer Awareness Month. Dedicated to supporting those impacted by brain cancer, the community goes “Grey In May” …

Cutting-Edge Antibody Arrays: Creative Biolabs Empowers Neuroscience and Stem Cell Research
As a leader in biotechnological solutions, Creative Biolabs has always been committed to providing innovative products to the scientific research community. SHIRLEY, NY, UNITED STATES, April 23, 2025 /EINPresswire.com/ -- In the wave of rapid …